These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26743240)

  • 41. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
    Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
    [No Abstract]   [Full Text] [Related]  

  • 43. Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.
    Haraguchi A; Fujishima K; Ando T; Mori F; Imaizumi M; Abiru N; Yamasaki H; Matsumoto K; Takamura N; Kawakami A
    Minerva Endocrinol; 2014 Dec; 39(4):289-97. PubMed ID: 25371055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
    Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME
    Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
    Ridge T; Moretto T; MacConell L; Pencek R; Han J; Schulteis C; Porter L
    Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
    Madsbad S
    Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
    Nelson P; Poon T; Guan X; Schnabel C; Wintle M; Fineman M
    Diabetes Technol Ther; 2007 Aug; 9(4):317-26. PubMed ID: 17705687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
    Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
    Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.
    McCormack PL
    Drugs; 2014 Mar; 74(3):325-51. PubMed ID: 24435322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
    Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
    Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
    Buse JB; Henry RR; Han J; Kim DD; Fineman MS; Baron AD;
    Diabetes Care; 2004 Nov; 27(11):2628-35. PubMed ID: 15504997
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
    Kendall DM; Riddle MC; Rosenstock J; Zhuang D; Kim DD; Fineman MS; Baron AD
    Diabetes Care; 2005 May; 28(5):1083-91. PubMed ID: 15855571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
    Levin PA; Mersey JH; Zhou S; Bromberger LA
    Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GLP-1 Agonists in Type 1 Diabetes Mellitus.
    Janzen KM; Steuber TD; Nisly SA
    Ann Pharmacother; 2016 Aug; 50(8):656-65. PubMed ID: 27252246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
    McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
    Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
    Henry RR; Logan D; Alessi T; Baron MA
    Clin Ther; 2013 May; 35(5):634-645.e1. PubMed ID: 23578605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
    Xu S; Liu X; Ming J; Ji Q
    Trials; 2016 Mar; 17():160. PubMed ID: 27009108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.
    Zhang X; Liu S; Li Y; Wang Y; Tian M; Liu G
    PLoS One; 2016; 11(6):e0156393. PubMed ID: 27304904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.